acute coronary syndrome. Acute ischaemic heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Loratadine, oral tablet, 10 mg daily for a one month course + Aspirin, oral tablet 80 mg daily + Metoral, oral tablet 25-50 mg towise in day. Intervention 2: Contro
Treatment - Drugs
Intervention group: Loratadine, oral tablet, 10 mg daily for a one month course + Aspirin, oral tablet 80 mg daily + Metoral, oral tablet 25-50 mg towise in day
Control group: Aspirint oral tablet 80 mg daily + Metoralt oral tablet 25-50 mg towice in day
Sponsors
Rafsanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: class 2 and 3 of Braunwald criteria Exclusion criteria: prior history of hospitalization due to acute coronary syndrome, presence of liver disease, using antihistamines drugs such drugs as Cimetidine, Erythromycin, Clarithromycin, anti-fungal group and Fluoxetine
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Readmission. Timepoint: Baseline, the first, second , third, and fourth week after the intervention. Method of measurement: Visual analog scale of readmission.;Recurrent angina. Timepoint: Baseline, the first, second , third, and fourth week after the intervention. Method of measurement: Descriptive scale of chest pain. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects of loratadine. Timepoint: Baseline, the first, second , third, and fourth week after the intervention. Method of measurement: Descriptive scale of symptoms such as headache, insomnia, weakness. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed